Contact Us

Phone 1300 884 450

MPA Makes PBAC Submission

PDS Update

MPA made a submission to the PBAC for the consideration of the reimbursement of Nivolumab (Opdivo) and ipilumimab (Yervoy) and we thank all those that contributed their stories. Real stories provide real insights and these are invaluable! The PBAC will meet in March to consider this treatment option for reimbursement and we will advise you of the outcomes once we have any news. MPA maintains that all patients deserve access to the best evidence based treatments available.

< Back to News

Sign up for Email Newsletter

Our quarterly e-newsletter includes the latest news, upcoming events and more.
  • This field is for validation purposes and should be left unchanged.